293 related articles for article (PubMed ID: 30820667)
1. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
[TBL] [Abstract][Full Text] [Related]
2. Generation of a neutralization-resistant CCR5 tropic simian/human immunodeficiency virus (SHIV-MK38) molecular clone, a derivative of SHIV-89.6.
Ishida Y; Yoneda M; Otsuki H; Watanabe Y; Kato F; Matsuura K; Kikukawa M; Matsushita S; Hishiki T; Igarashi T; Miura T
J Gen Virol; 2016 May; 97(5):1249-1260. PubMed ID: 26850058
[TBL] [Abstract][Full Text] [Related]
3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
4. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.
Shingai M; Donau OK; Schmidt SD; Gautam R; Plishka RJ; Buckler-White A; Sadjadpour R; Lee WR; LaBranche CC; Montefiori DC; Mascola JR; Nishimura Y; Martin MA
Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19769-74. PubMed ID: 23129652
[TBL] [Abstract][Full Text] [Related]
5. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
[TBL] [Abstract][Full Text] [Related]
6. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
[TBL] [Abstract][Full Text] [Related]
7. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
8. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM
J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to a CD4 mimic of a consensus clone of monkey-adapted CCR5-tropic SHIV-MK38C.
Matsuura K; Yamaura M; Sakawaki H; Himeno A; Pisil Y; Kobayakawa T; Tsuji K; Tamamura H; Matsushita S; Miura T
Virology; 2023 Jan; 578():171-179. PubMed ID: 36580864
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
11. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques.
Tsukamoto T; Yuasa M; Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
J Virol; 2007 Nov; 81(21):11640-9. PubMed ID: 17728225
[TBL] [Abstract][Full Text] [Related]
13. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
Kraft Z; Derby NR; McCaffrey RA; Niec R; Blay WM; Haigwood NL; Moysi E; Saunders CJ; Wrin T; Petropoulos CJ; McElrath MJ; Stamatatos L
J Virol; 2007 Jun; 81(12):6402-11. PubMed ID: 17392364
[TBL] [Abstract][Full Text] [Related]
14. Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.
Ziani W; Bauer A; Lu H; Wang X; Wu X; Bar KJ; Li H; Liu D; Shaw GM; Veazey RS; Xu H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568508
[TBL] [Abstract][Full Text] [Related]
15. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.
Gao N; Wang W; Wang C; Gu T; Guo R; Yu B; Kong W; Qin C; Giorgi EE; Chen Z; Townsley S; Hu SL; Yu X; Gao F
AIDS; 2018 Mar; 32(5):555-563. PubMed ID: 29239895
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
17. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
Viruses; 2018 May; 10(5):. PubMed ID: 29772652
[TBL] [Abstract][Full Text] [Related]
18. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
[TBL] [Abstract][Full Text] [Related]
19. Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.
Ren W; Mumbauer A; Gettie A; Seaman MS; Russell-Lodrigue K; Blanchard J; Westmoreland S; Cheng-Mayer C
J Virol; 2013 Jun; 87(11):6137-49. PubMed ID: 23514895
[TBL] [Abstract][Full Text] [Related]
20. Partial protection of SHIV-infected Chinese rhesus macaques against super-infection with heterologous SHIV isolate.
Li Y; Liu Q; Luo Z; Feng Y; Li Z; Wei Q; Shao Y
Curr HIV Res; 2012 Dec; 10(8):627-35. PubMed ID: 22954309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
